# Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults
Canonical URL: https://biopharmsignal.com/news/PCVX/vaxcyte-doses-first-participant-in-phase-1-study-evaluating-vax-a1-for-the-prevention-of-disease-caused-by-group-a-streptococcus-in-healthy-adults
Ticker: PCVX
Company: Vaxcyte
Source: Vaxcyte
Published: 2026-06-25 13:46 EST
Original Source URL: https://investors.vaxcyte.com
## Summary

First-in-Human Study Evaluating VAX-A1, a Potential Best-in-Class Vaccine Candidate Designed to Provide Broad Protection Against Disease Caused by Group A Streptococcus Two-Stage, Dose-Escalation Study Designed with Primary Objective to Evaluate Safety and Tolerability and Secondary Objective to

## Article Body
First-in-Human Study Evaluating VAX-A1, a Potential Best-in-Class Vaccine Candidate Designed to Provide Broad Protection Against Disease Caused by Group A Streptococcus Two-Stage, Dose-Escalation Study Designed with Primary Objective to Evaluate Safety and Tolerability and Secondary Objective to
## Recent Company News
- 2026-06-25 13:46 EST — [Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults](https://biopharmsignal.com/news/PCVX/vaxcyte-doses-first-participant-in-phase-1-study-evaluating-vax-a1-for-the-prevention-of-disease-caused-by-group-a-streptococcus-in-healthy-adults) — Source: Vaxcyte
- 2026-06-25 13:46 EST — [Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/PCVX/vaxcyte-reports-first-quarter-2026-financial-results-and-provides-business-update) — Source: Vaxcyte
- 2026-06-25 13:46 EST — [Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants](https://biopharmsignal.com/news/PCVX/vaxcyte-announces-commencement-of-proposed-public-offering-of-common-stock-and-pre-funded-warrants) — Source: Vaxcyte
- 2026-06-25 13:46 EST — [Vaxcyte Announces Pricing of $550 Million Public Offering](https://biopharmsignal.com/news/PCVX/vaxcyte-announces-pricing-of-550-million-public-offering) — Source: Vaxcyte
- 2026-06-25 13:46 EST — [Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares](https://biopharmsignal.com/news/PCVX/vaxcyte-announces-closing-of-632-5-million-public-offering-including-full-exercise-of-underwriters-option-to-purchase-additional-shares) — Source: Vaxcyte
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)